Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD)

First published 17/10/2014

Last updated 06/05/2025

EU PAS number:

EUPAS7708

Study

Ongoing

Documents

Study protocol

Updated protocol

2-79-52800-002_Protocol Amendment 8_Final Redacted_08Feb22 (3).pdf

First published: 24/04/2024

English (6.17 MB - PDF)View document

Study results

Study report

2-79-52800-002 synopsis_07Jan2022_no marks (2)

English (2.73 MB - PDF)View document

2-79-52800-002_synopsis_01Dec2011

English (477.98 KB - PDF)View document

2-79-52800-002_synopsis_10Jan2020

English (2.77 MB - PDF)View document

2-79-52800-002_synopsis_14Dec2015

English (2.28 MB - PDF)View document

2-79-52800-002_synopsis_20Dec2017

English (2.66 MB - PDF)View document

2-79-52800-002_synopsis_22Nov2013

English (119.03 KB - PDF)View document

2-79-52800-002_CSR Synopsis_06Dec23_No Redaction Marks_Final.pdf

English (2.74 MB - PDF)View document

Other information

Publications

Study publications

ENCePP Seal

ENCePP Seal documents

Secondary tabs